An overview of contraception in women with obesity

被引：1

作者：

Hammad, Wafaa Ali Belail ^{[1
]}

Gupta, Neerja ^{[2
]}

Konje, Justin C. ^{[3
,4
,5
]}

机构：

[1] Basildon & Thurrock Univ Hosp NHS Fdn Trust, Dept Obstet & Gynaecol, Basildon, England

[2] Basildon & Thurrock Univ Hosp NHS Fdn Trust, Basildon, England

[3] Feto Maternal Ctr, Doha, Qatar

[4] Weill Cornell Med, Obstet & Gynecol, Ar Rayyan, Qatar

[5] Univ Leicester, Dept Hlth Sci, Obstet & Gynaecol, Leicester, England

来源：

BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY | 2023年 / 91卷

关键词：

Obesity; Contraception; Pharmacokinetics; Safety; Combined hormonal contraception; Implants and lactational amenorrhea; DEPOT MEDROXYPROGESTERONE ACETATE; NONFATAL VENOUS THROMBOEMBOLISM; AMENORRHEA METHOD LAM; EMERGENCY CONTRACEPTION; ORAL-CONTRACEPTIVES; BODY-WEIGHT; INTRAUTERINE-DEVICE; ULIPRISTAL ACETATE; TRANSDERMAL PATCH; ETHINYL ESTRADIOL;

D O I：

10.1016/j.bpobgyn.2023.102408

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The use of safe and effective contraception is essential for pre-venting unplanned pregnancy in women of all body sizes. When counseling women with obesity about contraception, it is impor-tant to consider the pharmacokinetic alterations of obesity on various modern contraceptive methods. However, evidence is reassuring that most contraceptive methods are safe and effective in women with obesity. Individual countries and the World Health Organization have published Medical Eligibility Criteria to guide contraceptive selection in women with medical issues including obesity. When choosing contraception, specific risks of the method relative to any underlying medical disorders must also be balanced against the risks of unintended pregnancy in this group.(c) 2023 Elsevier Ltd. All rights reserved.

引用

页数：13

共 79 条

[1] Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use [J].

Abdollahi, M ;

Cushman, M ;

Rosendaal, FR .

THROMBOSIS AND HAEMOSTASIS, 2003, 89 (03) :493-498

[2] Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra™/Evra™) under conditions of heat, humidity, and exercise [J].

Abrams, LS ;

Skee, DM ;

Natarajan, J ;

Wong, FA ;

Leese, PT ;

Creasy, GW ;

Shangold, MM .

JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (12) :1301-1309

[3]

[Anonymous], 1977, Contraception, V15, P513

[4]

[Anonymous], 2016, US Medical Eligibility Criteria for Contraceptive Use

[5] Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol [J].

Bjarnadóttir, RI ;

Tuppurainen, M ;

Killick, SR .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (03) :389-395

[6] Early Weight Gain Related to Later Weight Gain in Adolescents on Depot Medroxyprogesterone Acetate [J].

Bonny, Andrea E. ;

Secic, Michelle ;

Cromer, Barbara .

OBSTETRICS AND GYNECOLOGY, 2011, 117 (04) :793-797

[7] A Longitudinal Comparison of Body Composition Changes in Adolescent Girls Receiving Hormonal Contraception [J].

Bonny, Andrea E. ;

Secic, Michelle ;

Cromer, Barbara A. .

JOURNAL OF ADOLESCENT HEALTH, 2009, 45 (04) :423-425

[8]

Boston Collaborative Drug Surveillance Program, Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mg of EE in relation to non-fatal venous thromboembolism, ischemic stroke, and myocardial infarction

[9] The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience [J].

Cleland, Kelly ;

Zhu, Haoping ;

Goldstuck, Norman ;

Cheng, Linan ;

Trussell, James .

HUMAN REPRODUCTION, 2012, 27 (07) :1994-2000

[10] Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users [J].

Cole, J. Alexander ;

Norman, Heather ;

Doherty, Michael ;

Walker, Alexander M. .

OBSTETRICS AND GYNECOLOGY, 2007, 109 (02) :339-346

← 1 2 3 4 5 6 7 8 →